Scroll Down
Spinal cord injury (SCI) occurs as a result of damage to the functional units of the spinal cord,
leading to life-altering consequences including chronic pain, paralysis and depression.
There is no current cure for SCI, only palliative care.
We have designed a 3D-bioprinted polycaprolactone (PCL) scaffold, coated in a mussel foot protein (MFP) bioadhesive.
We have incorporated a combinatorial approach that is supported by a growth-permitting enzyme.
Mussel Foot Protein (MFP)
3D printed polycaprolactone (PCL)
Chondroitinase ABC (ChABC)
Our therapy aims to encourage regeneration of severed axons with a specific focus on functional recovery. This is collectively targeted by the macro- and microarchitecture of the scaffold held securely in place by our MFP bioadhesive. ChABC will counteract the growth-inhibiting properties of the SCI lesion.
Through the convergence of 3D bioprinting, recombinant protein technology and synthetic biology, we are hoping to close the loop between SCI research and clinical therapy. Renervate Therapeutics strives to be the spark that revolutionises SCI treatment.
